Ignite Creation Date:
2024-05-06 @ 9:04 AM
Last Modification Date:
2024-10-26 @ 12:09 PM
Study NCT ID:
NCT02898116
Status:
COMPLETED
Last Update Posted:
2022-10-10
First Post:
2016-09-08
Brief Title:
Phase 12 Study of Ensartinib and Durvalumab in ALK-rearranged Non-small Cell Lung Cancer
Sponsor:
Ludwig Institute for Cancer Research
Organization:
Ludwig Institute for Cancer Research
Organization Data
Organization:
Ludwig Institute for Cancer Research
Class:
OTHER
Study ID:
LUD2014-012-ALK
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ludwig Institute for Cancer Research
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| MedImmune LLC | INDUSTRY |
| Xcovery Holdings Inc | INDUSTRY |
| Cancer Research Institute New York City | OTHER |